Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL286260 | 0.92 | GABRA1 (0.54) | GABRA1GABRA5 | |
| SCHEMBL286574 | 0.92 | GABRA1 (0.54) | GABRA1GABRA5 | |
| SCHEMBL286683 | 0.92 | GABRA1 (0.54) | GABRA1GABRA5 | |
| SCHEMBL286587 | 0.88 | GABRA1 (0.56) | GABRA1 | |
| SCHEMBL286449 | 0.87 | GABRA1 (0.48) | GABRA1GABRA5 | |
| SCHEMBL286795 | 0.86 | GABRA1 (0.48) | GABRA1 | |
| SCHEMBL287021 | 0.85 | GABRA1 (0.59) | GABRA1 | |
| SCHEMBL286627 | 0.85 | GABRA1 (0.54) | GABRA1GABRA5 | |
| SCHEMBL286650 | 0.85 | GABRA1 (0.48) | GABRA1GABRA5 | |
| SCHEMBL285878 | 0.84 | GABRA5 (0.67) | GABRA1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410104-B2 | Pyridazines | HOFFMANN-LA ROCHE INC. (US) | 2013-04-02 | — | — | US | claimed |
| EP-2427458-A1 | ISOXAZOLE-PYRIDAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-03-14 | — | — | EP | claimed |
| WO-2010127968-A1 | ISOXAZOLE-PYRIDAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | claimed |
| US-20100286159-A1 | PYRIDAZINES | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | claimed |
| EP-2427458-B1 | Isoxazole-pyridazine derivatives | HOFFMANN LA ROCHE (CH) | 2014-05-07 | — | — | EP | disclosed |
| US-8410104-B2 | Pyridazines | HOFFMANN-LA ROCHE INC. (US) | 2013-04-02 | — | — | US | disclosed |
| EP-2427458-A1 | ISOXAZOLE-PYRIDAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010127968-A1 | ISOXAZOLE-PYRIDAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286159-A1 | PYRIDAZINES | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286159-A1 | PYRIDAZINES | GABRA5, CHRNA5, GRIK5 | GABRA1 4/4885GABRA5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.